Why does a 300 mg nightly dose of oral micronized progesterone cause somnolence?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 9, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Why Progesterone Causes Drowsiness

Oral micronized progesterone at 300 mg nightly causes somnolence through its conversion to neuroactive metabolites, particularly allopregnanolone, which act as positive modulators of GABA-A receptors in the central nervous system, producing sedative and anxiolytic effects similar to benzodiazepines. 1, 2

Mechanism of Action

Neurosteroid Conversion and GABA-A Modulation:

  • Progesterone is metabolized to allopregnanolone and pregnanolone, both of which are potent positive modulators of the GABA-A receptor system, the major inhibitory neurotransmitter system in the mammalian central nervous system 3

  • These metabolites produce effects similar to other GABA-A modulators including benzodiazepines, barbiturates, and alcohol, resulting in sedation, anxiolysis, and anticonvulsant properties 3

  • When administered orally, progesterone undergoes extensive first-pass hepatic metabolism (>90%), producing unphysiologically high levels of these 5-alpha reduced metabolites, which directly cause dizziness and drowsiness 4

Clinical Implications and Dosing Strategy

Timing of Administration:

  • The sedative effect is specifically leveraged in clinical practice by administering oral micronized progesterone at bedtime, which minimizes daytime impairment while providing therapeutic benefit 2

  • The 300 mg dose mentioned in your question is within the standard range (200-400 mg daily) used in hormone replacement therapy, typically given as a single nighttime dose to exploit the sedative properties 1, 2

Route-Dependent Effects:

  • The drowsiness is significantly more pronounced with oral administration compared to vaginal routes, because vaginal progesterone bypasses first-pass hepatic metabolism and produces lower systemic levels of sedating metabolites 5, 4

  • Vaginal administration achieves therapeutic endometrial effects through direct uterine uptake while maintaining subphysiologic plasma progesterone levels, resulting in fewer central nervous system side effects 4

Biphasic Dose-Response Relationship

Important Caveat - The Inverted U-Shaped Curve:

  • Allopregnanolone exhibits a paradoxical biphasic effect: low to moderate concentrations (similar to physiological luteal phase levels) can produce anxiety and negative mood in susceptible women, while higher concentrations produce the expected sedative and anxiolytic effects 3

  • The 300 mg nightly dose typically produces concentrations in the higher range that favor sedation rather than the paradoxical anxiogenic effects seen at lower doses 3

  • Individual sensitivity varies considerably, with some women experiencing adverse mood effects while others tolerate progesterone well, likely related to differences in GABA-A receptor sensitivity 3

Comparison to Synthetic Progestins

Metabolic Differences:

  • Synthetic progestins (medroxyprogesterone acetate, norethindrone) are specifically designed to resist enzymatic degradation and produce different metabolites that do not have the same neurosteroid effects as natural progesterone 2, 6

  • While synthetic progestins may cause fatigue, dysphoria, and other side effects through different mechanisms, they do not produce the same GABA-A mediated sedation as micronized progesterone 6

  • Micronized natural progesterone is preferred specifically because its sedative effect is predictable, dose-dependent, and can be managed with nighttime dosing, whereas synthetic progestins produce more variable psychological side effects 1, 2

References

Research

Diagnostic and therapeutic use of oral micronized progesterone in endocrinology.

Reviews in endocrine & metabolic disorders, 2024

Research

Oral micronized progesterone.

Clinical therapeutics, 1999

Research

Uses of progesterone in clinical practice.

International journal of fertility and women's medicine, 1999

Guideline

Vaginal vs Oral Utrogestan Route Selection for Luteal Phase Support and Hormone Replacement Therapy

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Progesterone: review of safety for clinical studies.

Experimental and clinical psychopharmacology, 2007

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.